drugset / Trial / NCT00688909

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

NCT00688909

Phase 4 Completed 261 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole

Timeline

Start
2008-03
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral

Indications